Genfleet Therapeutics (shanghai), Inc. Class H · HKEX:2595
Genfleet Therapeutics (shanghai), Inc. Class H — Corporate Update (October 2025)
31 slides from Genfleet Therapeutics (shanghai), Inc. Class H's corporate update, Oct 27, 2025
Slide 1: GFH375/VS-7375 Program Update: Joint Presentation by GenFleet and Verastem
GFH375/VS-7375 Program Update: Joint Presentation by GenFleet and Verastem Oct. 27, 2025
Slide 2: GFH375: Dive in the ESMO Data and More
GFH375: Dive in the ESMO Data and More
Slide 3: Copyright, disclaimer and forward-looking statements
Copyright，disclaimer and forward-looking statements Specific information in this presentation may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as "predict", "believe", "plan", "predict", "expect", "will",
Slide 4: Efficacy and Safety of GFH375 Monotherapy in Previously Treated KRAS G12D PDAC
Efficacy and Safety of GFH375 Monotherapy in Previously Treated Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (PDAC) Aiping Zhou1, Zhihua Li2, Yuping Sun3, Zuoxing Niu4, Heshui Wu5, Lingjun Zhu6, Hong Zong7, Ying Yuan8, Zhengbo Song9, Ziming Li10, Lin Wu11, Xiujuan Qu12, Jingdong Zhang1
Slide 5: Best Overall Response
Abstract number: LBA84 Best Overall Response • ORR was 40.7% (24/59), 90%CI was [30%, 52%]. • DCR was 96.7% (57/59), 90%CI was [90%, 99%]. Majority (91.5%) had reduction in target lesions. Partial response Stable disease Best % changes from baseline in target lesions 50 Progressive disease 20 Change
Slide 6: Progression-Free Survival
Abstract number: LBA84 Progression-Free Survival • Median PFS was 5.52 months (90%CI: 4.27, 7.20), with a median follow-up time 5.65 months (90%CI: 4.96, 6.08). • 4-month PFS rate was 78.2% (90%CI: 69.8%, 87.5%). N=66, n (%) 1.00 No. of events 33 (50.0%) Progressive disease 27 (40.9%) Death 6 (9.1%)
Slide 7: Common Adverse Events
Abstract number: LBA84 Common Adverse Events • The safety profile of GFH375 in KRAS G12D mutant PDAC patients is consistent with previous report.1,2 – Common TRAEs were gastrointestinal and hematological AEs; most were grade 1 or 2 and manageable with supportive treatment. – Most frequent TRAEs (≥20
Slide 8: Post ESMO Focus: ORR Fluctuation
Post ESMO Focus: ORR Fluctuation Sample size PDAC baseline Prior treatment Line of patients Confidential 8
Slide 9: PDAC: ESMO Reported Baseline Characteristics
PDAC: ESMO Reported Baseline Characteristics 5 Confidential 9
Slide 10: PDAC: Worse Baseline Condition Compared to Competitors
PDAC: Worse Baseline Condition Compared to Competitors GFH3751 Zoldonrasib2 Daraxonrasib3 600 mg QD 150-1200 mg daily 300 mg daily N = 66 N = 104 N = 76 0 0 29% 34% ECOG PS 1 100% 71% 66% Median no. of PLoT (range) 2 (1-5) 2 (0-6) 2 (1-7) 1L 31.8% NA 49% 2L+ 68.2% NA 51% Prior treatment lines per So
Slide 11: PDAC: The Non-standard 1st-line Treatments in the Study
PDAC: The Non-standard 1st-line Treatments in the Study Participant 1st line Regimen 1 AG+S1+Nimotuzumab 2 AG+S1 3 AG+S1 4 AG + Sintilimab 5 AG+ Camrelizumab 6 NALIRIFOX+ Cadonilimab 7 GEM + OXA + Avastin + Sintilimab 8 AG + Lenvatinib 9 GS Confidential 11
Slide 12: PDAC: Subgroup Analysis - ORR
PDAC: Subgroup Analysis - ORR • 59 participants had measurable disease at baseline and at least one post-baseline tumor assessment All PDAC 2L 3L+ (N=59) (N=12) (N=47) ORR 40.68% 58.33% 36.17% [90%CI] [29.87%, 52.22%] [31.52%, 81.90%] [24.52%, 49.18%] DCR 96.61% 100% 95.74% [90%CI] [89.71%, 99.39%]
Slide 13: PDAC: Improved Efficacy Compared to Competitors
PDAC: Improved Efficacy Compared to Competitors 100 100 95.7 92 89 80 Percentage (%) 58.3 60 ORR DCR 36.2 35 40 22 20 0 GFH375 600mg QD GFH375 600mg QD Daraxonrasib 300mg daily Daraxonrasib 160-300mg daily Population 2L PDAC with KRAS G12Dm1 3L+ PDAC with KRAS G12Dm1 2L PDAC with KRAS G12Xm3 3L+ PDA
Slide 14: PDAC: Subgroup Analysis – PFS
PDAC: Subgroup Analysis – PFS All PDAC 2L 3L+ (N=66) (N=12) (N=54) Median PFS Not 5.52 5.52 (months) reached 4 No. of Events 33 (maturity: 29 33%) On Treatment 25 5 20 without Event Median follow-up time: 5.65 months Confidential 14
Slide 15: About AE Reporting in PDAC
About AE Reporting in PDAC • We reported TEAE in addition to TRAE • The only case of G4 liver tox was TEAE, not TRAE • Billiary tract obstruction due to enlarged lymphode which is not drug-related • The only case of G4 neutropenia was previously treated with immunotherapy • No new safety signal has
Slide 16: Cross-Trial Comparisons of Safety in PDAC
Cross-Trial Comparisons of Safety in PDAC • The overall safety/tolerability of GFH375 is better than that of daraxonrasib. GFH375 600mg QD1 Daraxonrasib 300mg daily2 2L+ PDAC, N=66 2L+ PDAC, N=83 1L PDAC, N=40 TRAE 100% 96% 95% G3 or above 31.8% 34% 35% Leading to discontinuation 3.0% 0 10% Leading
Slide 17: Common TRAEs in PDAC: GFH375 vs RMC-6236
Common TRAEs in PDAC: GFH375 vs RMC-6236 • GI Tox: Which one is better? Source: 1ESMO 2025. 2Events & Presentations | Revolution Medicines. • Hema Tox: No significant difference in G3 and above Abbreviations: 1L, first line. 2L+, second line and beyond. WBC, white blood cell. PLT, platelet. AST, asp
Slide 18: ICI Treatment is NOT Approved in PDAC, yet 33% Had Prior ICI
ICI Treatment is NOT Approved in PDAC, yet 33% Participants Had Prior ICI Treatment • The incidence of grade ≥3 TEAEs/TRAEs, TEAEs/TRAEs leading to treatment interruption, and SAEs/TRSAEs were higher in participants with prior ICI than in the ICI naïve participants (ESMO2025 data) AE, n (%) ICI pret
Slide 19: NSCLC: Better Efficacy in Pretreated Participants Compared to SoC
NSCLC: Better Efficacy in Pretreated Participants Compared to SoC • ORR: 68.8%, significant improved response compared to the SoC • mPFS was not reached. 68.8 1.00 4-month PFS rate >75% 29 26 0.75 12 PFS probability 0.50 1 2 3 4 GFH375 Immunochemotherapy Chemotherapy Immunotherapy 0.25 GFH375 SoC •
Slide 20: NSCLC: Improved Efficacy Compared to Competitors
NSCLC: Improved Efficacy Compared to Competitors • Best-in-class as G12D monotherapy for NSCLC • Supporting single-arm accelerated approval for 2L+ NSCLC 100 93.8 89 85 Percentage (%) 80 68.8 61 60 ORR 38 DCR 40 20 0 GFH375 600mg QD Zoldonrasib 1200mg daily Daraxonrasib 120-220mg daily Population 2L
Slide 21: Clinical Development Status of GFH375 and Competitors
Clinical Development Status of GFH375 and Competitors 2022 2023 2024 2025 2026 Q2 Q4 Q2 Q4 Q2 Q4 Q2 Q4 Q2 Q4 09/07/25 Pre. data readout (WCLC, NSCLC) Pre. data readout (ASCO, solid tumors) 06/02/25 PFS&OS readout (ESMO, PDAC) 10/19/25 GFH375 2025Q4 Ph3 LPI 07/09/24 FiH FPI Ph3 in 2L+ PDAC in 2L+ PDA
Slide 22: One of Global Leaders in Developing RAS-targeted Therapeutics
One of Global Leaders in Developing RAS-targeted Therapeutics Validation Efficiency • Mono: First-to-market in China, third globally Fulzerasib • Marketed product • First-to-market • Combo: potential 1st-line NSCLC standard-of-care speed of fulzerasib KRAS G12C • Proven expertise in development deve
Slide 23: Marching towards a Leading Pancreatic Cancer Franchise
Marching towards a Leading Pancreatic Cancer Franchise Diverse RAS-targeted therapies 80-90%* Pancreatic cancer patients with RAS mutations EGFR-Pan KRAS G12C KRAS G12D Pan RAS (ON) *Source: Seminars in Oncology RAS ADC GFH925 GFH375 GFH276 GFS784 Over 700 thousand Global incidence (2035E） World’s 1
Slide 24: Innovation, in expedition
Innovation, in expedition
Slide 25: Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers October 2025
Slide 26: Disclaimers
Disclaimers Forward-Looking Statements This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVM
Slide 27: VS-7375-101 Study Schema, Testing KRAS G12D+ Indications
VS-7375-101 Study Schema, Efficiently Testing KRAS G12D+ Indications with Monotherapy and SOC Combinations VS-7375 Monotherapy Part A: Single Agent Dose Escalation – Any KRAS G12D Solid Tumor Part B: Dose Expansion Cohort B1: 2L+ PDAC (N=20) Dose Level 3: 900 mg QD Dose Level 2: 600 mg QD The study
Slide 28: Accelerated Development Approach Builds on Preliminary First-in-Human Study Findings
Accelerated Development Approach Builds on Preliminary First-in-Human Study Findings Multi-Arm Clinical Study Evaluating FDA Engagement Plans Monotherapy and Combinations • Efficacious starting dose: • Granted Fast Track Designation for: • 400 mg starting dose supported by monotherapy • First-line i
Slide 29: VS-7375-101 Study Update as of October 23, 2025
VS-7375-101 Study Update as of October 23, 2025 • First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities (DLT’s) reported • Promising anti-tumor activity observed in patients with various solid tumors, including advanced pancreatic ductal adenocarcinoma
Slide 30: Next Steps in VS-7375 Clinical Program
Next Steps in VS-7375 Clinical Program Reported a Initiate the dose Subject to the results of Subject to the results of preliminary update escalation cohorts in the Phase 1 the combination dose on the Phase 1 combination with monotherapy dose escalation cohorts with monotherapy dose cetuximab, esc
Slide 31: Verastem Oncology
W YERASTEM ONCOLOGY
GenFleet Therapeutics (Shanghai) — Corporate Update (October 2025) on 6ix